C. Lawetz

Studyin a Phase 1b Multiple-Rising-Dose NS3 Protease Inhibitor Faldaprevir (BI Genotype 1-Infected Patients Receiving the Viral Resistance in Hepatitis C Virus

G. Kukolj, R. Bethell, M. Marquis, 2014 .

Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study

G. Kukolj, R. Bethell, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

Improved purification protocol of the HSV-1 protease catalytic domain, using immunoaffinity.

P. Bonneau, M. Massariol, G. McKercher, 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Antiviral Activity of a Selective Ribonucleotide Reductase Inhibitor against Acyclovir-Resistant Herpes Simplex Virus Type 1 In Vivo

J. Duan, N. Moss, M. Cordingley, 1998, Antimicrobial Agents and Chemotherapy.

The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.

M. Liuzzi, C. Lawetz, 1998, Antiviral research.

Specific inhibition of ribonucleotide reductases by peptides corresponding to the C-terminal of their second subunit.

S. Rakhit, P. Lavallée, N. Dansereau, 1991, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor.

B. Simoneau, S. Mason, M. Liuzzi, 2004, Nucleic acids research.

Inhibitors of Respiratory Syncytial Virus Replication Target Cotranscriptional mRNA Guanylylation by Viral RNA-Dependent RNA Polymerase

J. Rancourt, M. Massariol, S. Landry, 2005, Journal of Virology.

Interaction between Human Respiratory Syncytial Virus (RSV) M2-1 and P Proteins Is Required for Reconstitution of M2-1-Dependent RSV Minigenome Activity

S. Mason, M. Liuzzi, Erika Åberg, 2003, Journal of Virology.